

## Cystic Fibrosis Committee meeting 7

**Date:** 13/01/2016

**Location:** Royal College of Obstetricians and Gynaecologists, London.

**Minutes:** Confirmed



<b>Committee members present:</b>		
Martin Walshaw (Chair)		(Present for notes 1 – 6)
Mandy Bryon (MB)		(Present for notes 1 – 6)
Alexander Darlington (AD)		(Present for notes 1 – 6)
Iolo Doull (ID)		(Present for notes 1 – 6)
Sarah Collins (SC)		(Present for notes 1 – 6)
Alexander Darlington (AD)		(Present for notes 1 – 6)
Zoe Elliot (ZE)		(Present for notes 1 – 6)
Helen Parrott (HeP)		(Present for notes 1 – 6)
Janis Bloomer (JB)		(Present for notes 1 – 6)
Keith Thompson (KT)		(Present for notes 1 – 6)
Elaine Edwards (EE)		(Present for notes 1 – 6)
David Lacy (DL)		(Present for notes 1 – 6)
Nichola MacDuff (NM)		(Present for notes 1 – 6)

<b>In attendance:</b>		
Stephen Murphy (SM)	Clinical Director	(Present for notes 1 – 6)
Vanessa Delgado Nunes (VDN)	Senior Research Fellow and Guideline Lead	(Present for notes 1 – 6)
Annabel Flint (AF)	Project Manager	(Present for notes 1 – 6)
Melanie Powell (MP)	Assistant Project Manager	(Present for notes 1 – 6)
Shona Burman-Roy (SBR)	Senior Research Fellow	(Present for notes 4 – 6)
Omnia Abdulrazeg (OA)	Research Fellow	(Present for notes 1 – 6)
Gemma Villanueva (GV)	Research Fellow	(Present for notes 1 – 6)
Zosia Beckles (ZB)	Information Scientist	(Present for notes 1 – 6)

Hugo Pedder (HP)	Statistician	(Present for notes 1 – 6)
Gemma Marceniuk (GM)	Health Economist	(Present for notes 1 – 6)

<b>Observers:</b>	
None.	

<b>Apologies:</b>	
Katie Perryman-Ford	Guidelines Commissioning Manager
Helen McCabe (HM)	Committee member
Sarah Popple (SP)	Committee member

<b>1. Welcome and objectives for the meeting</b>				
<p>The Chair welcomed the Committee members and attendees to the seventh guideline committee meeting on Cystic Fibrosis. The Committee members and attendees introduced themselves.</p> <p>No members of the public asked to observe the meeting.</p> <p>The Chair informed the Committee that apologies had been received and these are noted above.</p> <p>The Chair outlined the objectives of the meeting, which included: the presentation of the evidence review and health economics for chronic antimicrobial treatment, the evidence review for immunomodulatory agents and acute antimicrobial treatment.</p>				
<b>2. Declarations of interest</b>				
<p>The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was the diagnosis and management of Cystic Fibrosis.</p> <p>The Chair asked everyone to verbally declare any interests that have arisen since the last meeting.</p>				
Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Zoe Elliott	Lay member	Parent member of the James Lind Alliance Priority	Personal non-financial, specific	Declare and participate

		<p>Setting Partnership in CF Steering Committee.</p> <p>I receive no payment for this. The steering committee is overseeing the project to ensure that as many community members as possible get involved and have their say over what they feel should be researched about the treatment and management of the condition. The end of the project will see the ten most popular questions being published, these may or may not become actual research projects in the future.</p>		
Keith Thompson	Senior Respiratory Pharmacist, Royal Brompton and Harefield NHS Foundation Trust	Member of the steering group for the James Lind Alliance Priority Setting Partnership in CF, which has no pharmaceutical industry representation or sponsorship. This project will seek to prioritise research questions in CF in conjunction with the 'CF community'	Personal non-financial, specific	Declare and participate

The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

### **3. Minutes of last meeting**

The Chair asked the Committee whether any changes were required to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate account of the meeting.

### **4. Presentations**

The Chair introduced GV, Research Fellow, and GM, Health economist, who gave a presentation on the evidence reviewed for the topic of antimicrobial prophylaxis. The Chair then led the committee through the process of drafting recommendations and LETRs for this topic.

The Chair introduced GV, Research Fellow, HP, Statistician, and GM, Health economist, who gave a presentation on the evidence review for the topic of chronic antimicrobial treatment (non-NMA outcome results). The Chair then led the committee through the process of drafting recommendations and LETRs for this topic.

GM then gave a presentation on the draft health economics for the topic of chronic antimicrobial treatment to suppress *P.aruginosa* and proposed model structure.

OA and HP presented the evidence review on immunomodulatory agents (NMA outcome results) and took questions from the Committee. The Chair then led the committee through the process of drafting recommendations for this topic.

The Committee thanked everyone for their presentations and contribution to the development of the guideline.

### **5. Questions and discussion**

### **6. Any other business**

There were no other items of business. MW thanked the Committee for attending and closed the meeting.

**Date of next meeting:** 01/03/16

**Location of next meeting:** Royal College of Obstetricians and Gynaecologists, London.